Cvijic Christine Mikail 4

What Happened
Christine Mikail Cvijic, President, Chief Financial Officer and a director of Neurogene Inc., sold a total of 9,600 shares in two open‑market transactions on May 6, 2026. The sales consisted of 4,800 shares at a weighted average price of $32.44 (proceeds $155,692) and 4,800 shares at a weighted average price of $30.07 (proceeds $144,351), for total proceeds of approximately $300,043. These were sales (not purchases) and were reported on a Form 4 filed May 8, 2026.

Key Details

• Transaction date: May 6, 2026 (reported May 8, 2026) — timely filing.
• Lots: 4,800 shares @ $32.44 (proceeds $155,692); 4,800 shares @ $30.07 (proceeds $144,351); total = 9,600 shares for ~$300,043.
• Price ranges (multiple trades): the $30.07 weighted average reflects trades in the $30.00–$30.31 range; the $32.44 weighted average reflects trades in the $32.02–$32.695 range. Reporting person can provide per‑trade breakdown on request (per footnotes).
• Plan/authority: Sales were effected pursuant to a 10b5‑1 trading plan adopted by Ms. Cvijic on August 18, 2025; the shares sold were held jointly by Ms. Cvijic and her spouse, David Cvijic.
• Holdings/awards noted in filing: unvested restricted stock units totaling 46,168 (10,635 vesting March 13, 2027; 13,533 vesting in equal installments March 26, 2027 & 2028; 22,000 vesting in equal installments Feb 20, 2027–2029). The filing also notes 9,600 shares held jointly by Ms. Cvijic and her spouse.

Context
These sales were executed under a pre‑arranged 10b5‑1 plan, which is commonly used by insiders to sell shares at predetermined times and is generally considered routine. Sales do not necessarily indicate negative views about the company; they can reflect diversification, tax planning, or other personal reasons. For retail investors, purchases by insiders tend to be more informative about confidence in the business, while planned sales like this are common.